PARIS, April 12, 2016 /PRNewswire/ --
Echosens [http://www.echosens.com/en ] extends its product range with the launch of a new FibroScan(R) product, the reference liver diagnosis equipment, at EASL 2016 in Barcelona: FibroScan(R) 530 Compact.
(Logo: http://photos.prnewswire.com/prnh/20160411/353647LOGO )
(Photo: http://photos.prnewswire.com/prnh/20160411/353648 )
The FibroScan(R) 530 Compact is designed to increase access to the exclusive FibroScan (R) VCTE(TM) (Vibration Controlled Transient Elastography) and CAP(TM) (Controlled Attenuation Parameter) technologies to monitor fibrosis, cirrhosis and steatosis. As a mobile, easy-to-handle and battery-operated device, FibroScan(R) [http://www.fibroscan.com/en/products ] 530 Compact extends availability for patients without access to centers with FibroScan(R) capabilities.
FibroScan(R) is supported by over 1,300 peer-reviewed publications and is the reference for the AASLD, EASL-ALEH, and WHO guidelines liver disease.
FibroScan(R) products, including the new FibroScan(R) models, are designed with several quality control systems to support consistency of scan results, irrespective of operator or location. This delivers comparability of results across locations, FibroScan(R) models, and operators. This consistency provides better information to support patient management, as well as a tool for tracking of results, publishing data and clinical research.
Echosens is taking the opportunity to provide ELPA [http://www.elpa-info.org ] (European Liver Patients Association) with its first FibroScan(R) 530 Compact at its booth (2200H) during EASL [http://www.easl.eu ] 2016 (the International Liver Congress(TM)) on 14th April at 3:30pm. This mobile device is intended to be used for non-profit liver screening campaigns throughout Europe.
Echosens is an innovative high-technology company based in France. Since its inception in 2001, Echosens has been recognized as the world's leading provider of non-invasive diagnostic devices for chronic liver diseases. The company's innovative, non-invasive technologies are recognized for cost effectively diagnosing and monitoring chronic liver diseases with precision, standardization and repeatability over time and users. The Group owns three products lines: FibroScan(R), FibroMeter(R), FibroView(R) which are covered by several families of patents owned by Echosens.
Facebook [https://www.facebook.com/fibroscan.echosens ] | Twitter [https://twitter.com/myliverexpert ] | LinkedIn [https://www.linkedin.com/company/echosens ] | YouTube [https://www.youtube.com/user/EchosensTV ]
For any further information, please contact:
Echosens Communication Dpt.